Clinical Trials · NCT06254014
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Beijing Dongfang Biotech Co., Ltd.
- Enrollment
- 270
- Start date
- Jul 2024
- Locations
- 1 site, China
- Primary endpoint
- HbA1c